

HOLLIS EDEN PHARMACEUTICALS INC /DE/

Form 8-K

September 24, 2003

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 24, 2002**

---

**HOLLIS-EDEN PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other

jurisdiction of incorporation)

**000-24672**  
(Commission

File No.)

**13-3697002**  
(IRS Employer

Identification No.)

**4435 Eastgate Mall, Suite 400**

**San Diego, California 92121**

(Address of principal executive offices and zip code)

**Registrant's telephone number, including area code: (858) 587-9333**

---

**Item 5. Other Events and Required FD Disclosure.**

On September 10, 2003, Hollis-Eden Pharmaceuticals, Inc. (the Company ) presented at the Roth Capital Partners New York Conference. A copy of the Company s presentation is attached hereto as Exhibit 99.1.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

**(c) Exhibits.**

<u>Number</u>	<u>Description</u>
99.1	Presentation delivered by the Company on September 10, 2003.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: September 24, 2003

By:

/s/ ERIC J. LOUMEAU

---

Eric J. Loumeau  
Vice President,

General Counsel and Secretary

**INDEX TO EXHIBITS**

99.1 Presentation delivered by the Company on September 10, 2003.